Aileron Therapeutics Inc (ALRN.OQ)
ALRN.OQ on NASDAQ Stock Exchange Global Market
5.12USD
2:18pm EDT
5.12USD
2:18pm EDT
Change (% chg)
$-0.07 (-1.35%)
$-0.07 (-1.35%)
Prev Close
$5.19
$5.19
Open
$5.22
$5.22
Day's High
$5.30
$5.30
Day's Low
$5.04
$5.04
Volume
3,796
3,796
Avg. Vol
9,752
9,752
52-wk High
$15.34
$15.34
52-wk Low
$5.01
$5.01
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
| Name | Age | Since | Current Position |
|---|---|---|---|
Jeffrey Bailey |
55 | 2018 | Chairman of the Board |
John Longenecker |
70 | 2018 | Interim President, Chief Executive Officer |
Evan Lippman |
2015 | Chief Financial Officer and Business Officer, Senior Vice President | |
Manuel Aivado |
2014 | Senior Vice President and Chief Medical Officer | |
D. Allen Annis |
2007 | Vice President - Biophysical and Analytical Technologies |
- BRIEF-Aileron Therapeutics Names John Longenecker As Interim CEO
- BRIEF-Aileron Therapeutics Q1 Loss Per Share $0.52
- BRIEF-Aileron Therapeutics Reports Q4 Loss Of $0.47 Per Share
- BRIEF-Aileron Therapeutics Appoints Jeffrey Bailey As Chairman Of Board
- BRIEF-Apple Tree Partners Sells 150,000 Shares Of Aileron Therapeutics Inc's Common Stock On Jan 9